126799-82-4

Basic information

• Product Name: 3-METHYLBENZYLAZIDE
• Synonyms: 3-METHYLBENZYLAZIDE;Methylbenzylazide;3-Methylbenzylazide 98%;1-(Azidomethyl)-3-methylbenzene
• CAS NO: 126799-82-4
• Molecular Formula: C₈H₉N₃
• Molecular Weight: 147.18
• Mol File: 126799-82-4.mol

Chemical Properties

• Boiling Point: 63-65°C 0,1mm
• Appearance: /
• CAS DataBase Reference: 3-METHYLBENZYLAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHYLBENZYLAZIDE(126799-82-4)
• EPA Substance Registry System: 3-METHYLBENZYLAZIDE(126799-82-4)

Safety Data

• Hazard Codes: C,T
• Statements: 2-11
• Safety Statements: 15-17-33
• RIDADR: 1993
• Hazardous Substances Data: 126799-82-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-Methylbenzylazide is used as a reagent in organic synthesis for the creation of various nitrogen-containing compounds. Its unique properties allow it to serve as a building block in the development of new materials and products.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 3-Methylbenzylazide is utilized in the synthesis of drugs, contributing to the development of new medicinal compounds due to its reactive nature and ability to form complex molecular structures.
Used in Agrochemical Production:
3-Methylbenzylazide also finds application in the agrochemical sector, where it is employed in the production of pesticides and other agricultural chemicals, enhancing the effectiveness of these products through its reactive properties.
Used in Research and Development:
Due to its explosive and highly reactive nature, 3-Methylbenzylazide is extensively used in research for exploring its potential in creating new compounds and materials, pushing the boundaries of chemical innovation and application.

Upstream product

• 108-38-3 m-xylene 
• 620-13-3 1-bromomethyl-3-methyl-benzene 
• 14503-41-4 m-methylbenzyl tosylate 
• 620-19-9 1-chloromethyl-3-methyl-benzene 
• 96258-53-6 Methanesulfonic acid 3-methyl-benzyl ester 
• 587-03-1 3-methylbenzyl alcohol 
• 620-23-5 m-tolyl aldehyde 

Downstream Products

• 93416-42-3 5-amino-1-(m-methylbenzyl)-1H-1,2,3-triazole-4-carboxamide 
• 1093305-39-5 N₂,N₂-dimethyl-N₁-{5-[1-(3-methylbenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-yl}glycinamide 
• 1130489-21-2 CH₃C₆H₄CH₂C₂N₃(Si(CH₃)3)BO₂C₆H₁₂ 
• 1190693-53-8 C₁₈H₁₉N₃O 
• 1190693-54-9 C₁₈H₁₉N₃O 
• 1190693-32-3 C₁₉H₂₁N₃ 
• 1190693-33-4 C₁₉H₂₁N₃ 
• 1190693-08-3 C₁₉H₂₃N₃Si 
• 126800-03-1 1‐(3‐methylbenzyl)‐4‐phenyl‐1H‐1,2,3‐triazole 
• 126800-27-9 ethyl 1-(3-methylbenzyl)-1H-1,2,3-triazole-4-carboxylate 
• 1370251-42-5 N-((1-(3-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-amine 
• 1399679-60-7 1-(3-methylbenzyl)-4-[(phenylselanyl)methyl]-1H-1,2,3-triazole 
• 1447816-07-0 C₂₉H₂₆N₄O 
• 1447816-35-4 C₃₇H₃₅N₇O 

Relevant articles and documents

Modular o-quinone catalyst system for dehydrogenation of tetrahydroquinolines under ambient conditions

Quinolines are common pharmacophores present in numerous FDA-approved pharmaceuticals and other bioactive compounds. Here, we report the design and development of new o-quinone-based catalysts for the oxidative dehydrogenation of tetrahydroquinolines to afford quinolines. Use of a Co(salophen) cocatalyst allows the reaction to proceed efficiently with ambient air at room temperature. The utility of the catalytic method is demonstrated in the preparation of a number of medicinally relevant quinolines.

Study of selected benzyl azides by UV photoelectron spectroscopy and mass spectrometry

Benzyl azide and the three methylbenzyl azides were synthesized and characterized by mass spectrometry (MS) and ultraviolet photoelectron spectroscopy (UVPES). The electron ionization fragmentation mechanisms for benzyl azide and their methyl derivatives

Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus

Inspired by our previous efforts on the modifications of diarylpyrimidines as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTI) and reported crystallography study, novel diarylnicotinamide derivatives were designed with a “triazole tail” occupying the entrance channel in the NNRTI binding pocket of the reverse transcriptase to afford additional interactions. The newly designed compounds were then synthesized and evaluated for their anti-HIV activities in MT-4 cells. All the compounds showed excellent to good activity against wild-type HIV-1 strain with EC50 of 0.02–1.77 μM. Evaluations of selected compounds against more drug-resistant strains showed these compounds had advantage of inhibiting E138K mutant virus which is a key drug-resistant mutant to the new generation of NNRTIs. Among this series, propionitrile (3b2, EC50(IIIB) = 0.020 μM, EC50(E138K) = 0.015 μM, CC50 = 40.15 μM), pyrrolidin-1-ylmethanone (3b8, EC50(IIIB) = 0.020 μM, EC50(E138K) = 0.014 μM, CC50 = 58.09 μM) and morpholinomethanone (3b9, EC50(IIIB) = 0.020 μM, EC50(E138K) = 0.027 μM, CC50 = 180.90 μM) derivatives are the three most promising compounds which are equally potent to the marketed drug Etravirine against E138K mutant strain but with much lower cytotoxicity. Furthermore, detailed SAR, inhibitory activity against RT and docking study of the representative compounds are also discussed.

Discovery of phenylalanine derivatives as potent HIV-1 capsid inhibitors from click chemistry-based compound library

The HIV-1 capsid (CA) protein plays essential roles in both early and late stages of HIV-1 replication and is considered an important, clinically unexploited therapeutic target. As such, small drug-like molecules that inhibit this critical HIV-1 protein h

Synthesis and muscarinic acetylcholine receptor (mAChR) antagonist activity of substituted piperazine-triazoles

This study describes synthesis of a series of piperazine-triazole derivatives and their ex vivo evaluation for preliminary muscarinic acetylcholine receptor (mAChR) blocking activity on rat ileum model. A molecule based on benzonitrile piperazine triazole scaffold showed good tissue relaxation and blocking of neurotransmitter ACh in the ex vivo experiment. Graphic abstract: [Figure not available: see fulltext.]

Synthesis, Docking, and Biological activities of novel Metacetamol embedded [1,2,3]-triazole derivatives

ERα controls the breast tissue development and progression of breast cancer. In our search for novel compounds to target Estrogen Receptor Alpha Ligand-Binding Domain, we identified “N-(3-((1H-1,2,3-triazol-4-yl)methoxy)phenyl)acetamide” derivatives as lead compounds. The Docking studies indicated good docking score for Metacetamol derivatives when docked into the 1XP6. A series of metacetamol derivatives have been synthesized, characterized and evaluated for cytotoxicity, anti bacterial and anti oxidant activities. Among the tested twelve hybrid compounds, “7a, 7g, 7h and 7i” derivatives showed promising cytotoxicity with IC50 value of 50 value of 30 μM, whereas Compounds “7a, 7b, 7c, 7d, 7g, 7j, 7k and 7l” showed moderate anti bacterial activity with the MIC value of 300 μM.

NOVEL DIBENZOOXAPHOSPHININE OXIDE DERIVATIVE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE DISEASE COMPRISING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a novel dibenzooxininin oxide derivative compound having various nitrogen-containing substituents introduced at 6-position of a dibenzooxaphosphorin oxide mononuclear, and to the use thereof. The present invention relates to a pharmaceutical composition for preventing or treating degenerative diseases and a health supplement food composition for preventing or treating degenerative diseases, comprising the dibenzooxaphosphorin oxide derivative compound of the present invention.

Dipolar HCP materials as alternatives to DMF solvent for azide-based synthesis

Hypercrosslinked polymers HCP-DMF and HCP-DMF-SO3H containing abundant and flexible DMF moieties were designed and synthesized. Benefitting from the solvation microenvironment provided by the pseudo-DMF moities, the polar HCPs manifested outstanding performances in the conversions of NaN3 to benzylic azides and 1,2,3-triazoles in EtOH (95%), respectively, avoiding the use of risky DMF and improving the separation processes of the products.

Synthesis of 1,2,3-triazole benzophenone derivatives and evaluation of in vitro sun protection, antioxidant properties, and antiproliferative activity on HT-144 melanoma cells

Benzophenones display several biological activities, including antioxidant, anticancer, and photoprotective. Furthermore, antioxidants can minimize both ultraviolet absorption and tumor development. In the present investigation, a series of twenty-six 1,2

Synthesis of 1,2,3,triazole modified analogues of hydrochlorothiazide via click chemistry approach and in-vitro α-glucosidase enzyme inhibition studies

The current study was aimed to discover potent inhibitors of α-glucosidase enzyme. A 25 membered library of new 1,2,3-triazole derivatives of hydrochlorothiazide (1) (HCTZ, a diuretic drug also being used for the treatment of high blood pressure) was synt